Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
IRADIMED Community
NasdaqGM:IRMD Community
1
Narratives
written by author
0
Comments
on narratives written by author
8
Fair Values set
on narratives written by author
Create a narrative
Community Investing Ideas
IRADIMED
Popular
Undervalued
Overvalued
IRADIMED
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Company Will Launch 3870 MR IV Pump And Expand Capacity With New Facility
Key Takeaways Focus on the 3870 MR IV pump is expected to drive long-term revenue growth, with expanded sales and market penetration enhancing future earnings. New facility and increased infrastructure investments aim to boost capacity and efficiency, supporting stable margins and long-term revenue growth despite initial expenses.
View narrative
US$71.00
FV
2.0% undervalued
intrinsic discount
8.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
7 days ago
author updated this narrative
Your Valuation for
IRMD
IRMD
IRADIMED
Your Fair Value
US$
Current Price
US$69.57
9.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
125m
2015
2018
2021
2024
2025
2027
2030
Revenue US$125.3m
Earnings US$33.3m
Advanced
Set Fair Value